Acute exposure to estrogenic chemicals is shown herein to induce DNA damage mediated by formation of ERα-dependent R-loops. Disclosed herein are methods for evaluating the safety and activity of a xenoestrogen. Also disclosed are methods for identifying subject particularly susceptible to the genotoxic effects of endogenous estrogens or environmental xenoestrogens. This method can be used to select suitable hormone therapies, such as a selective estrogen receptor modulator (SERM), aromatase inhibitor, or selective estrogen receptor degrader (SERD).

Provided is a method suitable for concentrating the viruses present in the environment, food or biomaterials in fields such as inspections for ensuring public or food safety and medical examinations, and reagents used therein. By adding an optimum concentration of polysaccharide such as glycogen to polyethylene glycol (PEG) and optimizing the concentration of a salt to be added, the viruses suspended in an aqueous solution can be easily, rapidly and stably recovered at a high recovery rate.

Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.

A method for producing a library for use in prediction of the action of a substance of interest on a living organism, the library having a large number of numerical data obtained based on change in a behavioral parameter of zebrafish and a large number of numerical data representing change in expression levels of genes integrated and recorded therein.

The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such as treatment with a secretory phospholipase A.sub.2 (sPLA.sub.2) hydrolysable, cisplatin-containing liposome. The invention further includes methods of treating a patient having cancer by administering, e.g., the liposome.

The present invention relates to three-dimensional (3D) tissue constructs and methods of using such 3D tissue constructs to screen for neurotoxic agents. In particular, provided herein are methods of producing and using complex, highly uniform human tissue models comprising physiologically relevant human cells, where the tissue models have the degree of sample uniformity and reproducibility required for use in quantitative high-throughput screening applications.

A method of selecting an agent for treating a disease of a subject is disclosed which includes identifying genes which bring about resistance to a cytotoxic agent in haploid human embryonic stem (ES) cells. Once the gene is identified, the method includes analyzing the sequence and/or expression of the gene in a cell sample of the subject, wherein an alteration in the sequence and/or level of expression of the gene as compared to the sequence and/or expression of the gene in a control sample is indicative that the agent should be ruled out as a monotherapy for treating the disease in the subject.

A method determines the likelihood that a subject has or will develop cancer. The method is based on identifying whether targeted somatic mutagenesis of a nucleic acid molecule by a mutagenic agent has occurred. The mutations are at one or more motifs recognized or targeted by the mutagenic agent such as AID, an APOBEC cytidine deaminase or aflatoxin, The nucleic acid molecule includes the whole exome. The cancer can be any of breast, prostate, liver, colon, pancreatic, skin, cervical, lymphoid, hematopoietic and ovarian cancer; and the biological sample comprises, respectively, breast, prostate, liver, colon, pancreatic, skin, cervical, lymphoid, hematopoietic or ovarian tissue or cells.

The invention relates to methods and systems for high-throughput toxicity screening of compounds using Mahalanobis Values, and in particular comparing a normal unexposed transcriptome Mahalanobis Value in an in-vitro hepatocyte microassay against a calculated transcriptome Mahalanobis Value of hepatocytes exposed to a target compound for varying time periods and in varying concentrations.

The present disclosure relates generally to methods and/or means for generating and analyzing gene expression profiles of a microorganism isolated from an environment contaminated with toxic organic compounds. In particular, the disclosure relates to methods and/or means of identifying genes, enzymes, and metabolic pathways involved in naphthenic acids compounds (NAFC) or naphthenic acid (NA) degradation activity. Engineered microorganisms with increased naphthenic acid (NA) degradation activity and their use for biodegradation of toxic organic compounds in contaminated environments are further provided.